바이오에너텍

비상장

Bioenertech.,Co,Ltd

김기환

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

바이오에너텍

Business Reg. No. 6858101982 · CEO 김기환

I.Investment Overview

Target바이오에너텍 (6858101982)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명바이오에너텍
영문명Bioenertech.,Co,Ltd
대표자김기환
사업자등록번호6858101982
법인등록번호1611110031238
설립일2020.08.18

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW0.1202143.320221012023109.52024143.62025
영업이익100M KRW-6.52021-10.920223.920230.6202410.72025
순이익100M KRW-6.72021-14.12022-1.82023-3.8202482025
Item20252024202320222021
자산총계336.1억원298.3억원245.9억원245.8억원230.2억원
부채총계155.2억원125.4억원169.2억원167.3억원137.5억원
자본총계180.9억원172.9억원76.7억원78.5억원92.7억원
매출액143.6억원109.5억원101억원43.3억원1,026만원
영업이익10.7억원5,583만원3.9억원-10.9억원-6.5억원
순이익8억원-3.8억원-1.8억원-14.1억원-6.7억원

VI.Financial Ratios

FY2025 basis

7.43%

영업이익률

5.57%

순이익률

2.38%

ROA

4.42%

ROE

85.8%

부채비율

53.82%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

바이오에너텍 투심보고서 | Alpha Lenz